Phreesia, Inc. (NYSE:PHR) Receives $31.62 Average PT from Analysts

Shares of Phreesia, Inc. (NYSE:PHR - Get Free Report) have received an average recommendation of "Moderate Buy" from the fourteen brokerages that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $31.62.

A number of analysts have recently commented on PHR shares. Raymond James reissued an "outperform" rating and issued a $30.00 price objective (up previously from $25.00) on shares of Phreesia in a research note on Friday, March 15th. DA Davidson reiterated a "neutral" rating and issued a $32.00 target price on shares of Phreesia in a report on Friday, March 15th. Truist Financial started coverage on shares of Phreesia in a report on Monday, February 26th. They issued a "buy" rating and a $35.00 target price on the stock. JMP Securities upped their price target on Phreesia from $28.00 to $30.00 and gave the company a "market outperform" rating in a report on Thursday, March 21st. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $29.00 price target on shares of Phreesia in a report on Friday, March 15th.

Insider Activity

In other Phreesia news, General Counsel Allison C. Hoffman sold 5,549 shares of the company's stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $22.62, for a total value of $125,518.38. Following the transaction, the general counsel now owns 141,485 shares in the company, valued at approximately $3,200,390.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, COO Evan Roberts sold 25,962 shares of the stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $23.52, for a total value of $610,626.24. Following the transaction, the chief operating officer now owns 728,570 shares in the company, valued at $17,135,966.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Allison C. Hoffman sold 5,549 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $22.62, for a total value of $125,518.38. Following the completion of the transaction, the general counsel now owns 141,485 shares in the company, valued at approximately $3,200,390.70. The disclosure for this sale can be found here. Insiders have sold 73,516 shares of company stock worth $1,695,194 in the last 90 days. Company insiders own 5.80% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. CI Investments Inc. lifted its position in shares of Phreesia by 6.6% in the third quarter. CI Investments Inc. now owns 477,265 shares of the company's stock worth $8,915,000 after buying an additional 29,500 shares during the last quarter. Schroder Investment Management Group acquired a new stake in Phreesia in the 3rd quarter worth approximately $6,514,000. TimesSquare Capital Management LLC boosted its position in Phreesia by 7.8% during the third quarter. TimesSquare Capital Management LLC now owns 774,079 shares of the company's stock worth $14,460,000 after purchasing an additional 55,793 shares during the period. Trust Point Inc. acquired a new position in Phreesia during the fourth quarter valued at approximately $239,000. Finally, Lazard Asset Management LLC raised its position in shares of Phreesia by 58.6% in the third quarter. Lazard Asset Management LLC now owns 424,047 shares of the company's stock valued at $7,921,000 after purchasing an additional 156,711 shares during the period. Institutional investors and hedge funds own 92.10% of the company's stock.

Phreesia Price Performance

Shares of PHR stock traded up $0.25 during midday trading on Tuesday, reaching $23.00. 349,243 shares of the company were exchanged, compared to its average volume of 524,624. Phreesia has a 12 month low of $12.05 and a 12 month high of $34.98. The company has a market cap of $1.30 billion, a P/E ratio of -9.04 and a beta of 0.92. The company's 50 day moving average price is $24.64 and its two-hundred day moving average price is $21.20. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.78 and a current ratio of 1.78.

Phreesia (NYSE:PHR - Get Free Report) last announced its earnings results on Thursday, March 14th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.02. Phreesia had a negative return on equity of 53.33% and a negative net margin of 38.42%. The firm had revenue of $95.00 million for the quarter, compared to analysts' expectations of $93.52 million. During the same quarter in the previous year, the company earned ($0.72) earnings per share. The firm's quarterly revenue was up 24.0% compared to the same quarter last year. On average, sell-side analysts expect that Phreesia will post -1.48 earnings per share for the current year.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.